NYSE:DVA - DaVita Stock Price, Price Target & More

Get Started

$67.89 -0.20 (-0.29 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$67.89

Today's Range$67.77 - $68.57

52-Week Range$52.51 - $80.71

Volume875,526 shs

Average Volume1.56 million shs

Market Capitalization$11.88 billion

P/E Ratio18.40

Dividend YieldN/A

Beta1.1

About DaVita (NYSE:DVA)

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

Receive DVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified

Sub-IndustryHealth Care Services

SectorMedical

SymbolNYSE:DVA

CUSIP23918K10

Webwww.davita.com

Phone303-405-2100

Debt

Debt-to-Equity Ratio1.94

Current Ratio2.94

Quick Ratio2.90

Price-To-Earnings

Trailing P/E Ratio18.40

Forward P/E Ratio16.56

P/E Growth0.99

Sales & Book Value

Annual Sales$10.88 billion

Price / Sales1.09

Cash Flow$7.6799 per share

Price / Cash8.84

Book Value$27.40 per share

Price / Book2.48

Profitability

EPS (Most Recent Fiscal Year)$3.32

Net Income$663.61 million

Net Margins2.94%

Return on Equity13.84%

Return on Assets3.61%

Miscellaneous

Employees74,500

Outstanding Shares174,500,000

DaVita (NYSE:DVA) Frequently Asked Questions

What is DaVita's stock symbol?

DaVita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

How will DaVita's stock buyback program work?

DaVita declared that its Board of Directors has approved a share repurchase program on Wednesday, October 11th 2017, which allows the company to repurchase $1,500,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's leadership believes its stock is undervalued.

How were DaVita's earnings last quarter?

DaVita (NYSE:DVA) announced its earnings results on Thursday, May, 3rd. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.13. The company earned $2.85 billion during the quarter, compared to the consensus estimate of $2.79 billion. DaVita had a net margin of 2.94% and a return on equity of 13.84%. The firm's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.79 earnings per share. View DaVita's Earnings History.

When is DaVita's next earnings date?

DaVita is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for DaVita.

What price target have analysts set for DVA?

10 equities research analysts have issued 12 month target prices for DaVita's stock. Their predictions range from $60.00 to $97.00. On average, they expect DaVita's share price to reach $81.1250 in the next twelve months. View Analyst Ratings for DaVita.

Who are some of DaVita's key competitors?

Some companies that are related to DaVita include Fresenius Medical Care (FMS), Tivity Health (TVTY), American Renal Associates (ARA), Catasys (CATS), Caladrius Biosciences (CLBS), BioRestorative Therapies (BRTX), Pacific Health Care Organization (PFHO), CNS Response (MYND), Hooper Holmes (HPHW) and American Caresource (GNOW).

Who are DaVita's key executives?

DaVita's management team includes the folowing people:

Mr. Kent J. Thiry, Chairman & CEO (Age 62)
Mr. James K. Hilger, Chief Accounting Officer (Age 56)
Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 50)
Mr. Javier J. Rodriguez, Chief Exec. Officer of Kidney Care (Age 47)
Ms. LeAnne M. Zumwalt, Group VP of Purchasing & Public Affairs (Age 59)

Has DaVita been receiving favorable news coverage?

News coverage about DVA stock has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DaVita earned a media sentiment score of 0.14 on Accern's scale. They also assigned news articles about the company an impact score of 46.26 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are DaVita's major shareholders?

DaVita's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.09%), Manning & Napier Group LLC (2.09%), Dimensional Fund Advisors LP (1.58%), OppenheimerFunds Inc. (1.47%), Northern Trust Corp (1.19%) and Neuberger Berman Group LLC (1.18%). Company insiders that own DaVita stock include Charles Berg, James K Hilger, Javier Rodriguez, Jeanine Marie Jiganti, Kent J Thiry, Leanne M Zumwalt, Michael David Staffieri and William L Roper. View Institutional Ownership Trends for DaVita.

Which major investors are selling DaVita stock?

DVA stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, FIL Ltd, Neuberger Berman Group LLC, Manning & Napier Group LLC, DekaBank Deutsche Girozentrale, BlackRock Inc., Prudential Financial Inc. and Sei Investments Co.. Company insiders that have sold DaVita company stock in the last year include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt and William L Roper. View Insider Buying and Selling for DaVita.

Which major investors are buying DaVita stock?

DVA stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Boston Partners, Wedge Capital Management L L P NC, Old Mutual Global Investors UK Ltd., Rock Springs Capital Management LP, Pendal Group Ltd, Mackay Shields LLC and Toronto Dominion Bank. View Insider Buying and Selling for DaVita.

How do I buy shares of DaVita?

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DaVita's stock price today?

One share of DVA stock can currently be purchased for approximately $67.89.

How big of a company is DaVita?

DaVita has a market capitalization of $11.88 billion and generates $10.88 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.32 on an earnings per share basis. DaVita employs 74,500 workers across the globe.

How can I contact DaVita?

DaVita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]

MarketBeat Community Rating for DaVita (DVA)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		337 (Vote Outperform)
Underperform Votes:		357 (Vote Underperform)
Total Votes:		694

MarketBeat's community ratings are surveys of what our community members think about DaVita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

DaVita (NYSE:DVA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

10 Wall Street analysts have issued ratings and price targets for DaVita in the last 12 months. Their average twelve-month price target is $81.1250, suggesting that the stock has a possible upside of 19.49%. The high price target for DVA is $97.00 and the low price target for DVA is $60.00. There are currently 4 hold ratings, 4 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Hold
Consensus Rating Score:	2.80	2.64	2.64	1.89
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 4 Buy Rating(s) 2 Strong Buy Rating(s)	1 Sell Rating(s) 4 Hold Rating(s) 4 Buy Rating(s) 2 Strong Buy Rating(s)	1 Sell Rating(s) 4 Hold Rating(s) 4 Buy Rating(s) 2 Strong Buy Rating(s)	2 Sell Rating(s) 6 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$81.1250	$79.00	$79.00	$63.00
Price Target Upside:	19.49% upside	5.86% upside	5.86% upside	14.57% upside

DaVita (NYSE:DVA) Consensus Price Target History

Price Target History for DaVita (NYSE:DVA)

DaVita (NYSE:DVA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/14/2018	SunTrust Banks	Reiterated Rating	Hold	$80.00	Medium
2/13/2018	Robert W. Baird	Set Price Target	Buy	$97.00	High
1/11/2018	Bank of America	Reiterated Rating	Buy	$85.00 ➝ $92.00	High
12/11/2017	Citigroup	Upgrade	Neutral ➝ Buy	$67.71 ➝ $82.00	Medium
12/7/2017	JPMorgan Chase & Co.	Boost Price Target	Outperform ➝ Strong-Buy	$4.90 ➝ $84.00	Low
12/7/2017	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$65.00 ➝ $84.00	High
12/6/2017	KeyCorp	Reiterated Rating	Hold		Low
11/8/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$64.00 ➝ $60.00	N/A
10/23/2017	Wolfe Research	Upgrade	Market Perform ➝ Outperform		N/A
8/3/2017	Jefferies Group	Reiterated Rating	Hold	$70.00	Medium
5/25/2017	Goldman Sachs Group	Reiterated Rating	Sell	$62.00	High
11/1/2016	Wells Fargo & Co	Reiterated Rating	Outperform		N/A

(Data available from 5/26/2016 forward)

DaVita (NYSE:DVA) Earnings History and Estimates Chart

Earnings by Quarter for DaVita (NYSE:DVA)

DaVita (NYSE:DVA) Earnings Estimates

2018 EPS Consensus Estimate: $4.02
2019 EPS Consensus Estimate: $4.56

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.88	$0.93	$0.91
Q2 2018	2	$0.98	$1.04	$1.01
Q3 2018	2	$1.03	$1.04	$1.04
Q4 2018	2	$1.01	$1.12	$1.07
Q1 2019	2	$1.04	$1.06	$1.05
Q2 2019	2	$1.14	$1.15	$1.15
Q3 2019	2	$1.17	$1.17	$1.17
Q4 2019	2	$1.16	$1.22	$1.19

DaVita (NYSE DVA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/30/2018		$0.98					N/A
5/3/2018	Q1 2018	$0.92	$1.05	$2.7883 billion	$2.8494 billion	View	N/A
2/13/2018	Q4 2017	$0.94	$0.92	$3.8959 billion	$2.7809 billion	View	Listen
11/7/2017	Q3 2017	$0.94	$0.81	$3.9076 billion	$3.9228 billion	View	N/A
8/1/2017	Q2 2017	$0.90	$0.92	$3.8170 billion	$3.8775 billion	View	Listen
5/2/2017	Q1 2017	$0.8150	$0.79	$3.6882 billion	$3.6973 billion	View	Listen
2/16/2017	Q4 2016	$0.91	$0.98	$3.74 billion	$3.7157 billion	View	Listen
11/2/2016	Q316	$0.94	$0.95	$3.72 billion	$3.73 billion	View	Listen
8/8/2016	Q216	$0.98	$1.01	$3.67 billion	$3.72 billion	View	Listen
5/4/2016	Q116	$0.86	$0.92	$3.51 billion	$3.58 billion	View	Listen
2/11/2016	Q415	$0.97	$1.01	$3.50 billion	$3.5336 billion	View	Listen
11/3/2015	Q315	$0.97	$1.00	$3.46 billion	$3.5257 billion	View	Listen
8/4/2015	Q215	$0.95	$0.95	$3.37 billion	$3.4346 billion	View	Listen
5/4/2015	Q115	$0.86	$0.86	$3.25 billion	$3.2880 billion	View	Listen
2/12/2015	Q414	$0.89	$0.96	$3.26 billion	$3.3280 billion	View	Listen
11/6/2014	Q314	$0.91	$0.90	$3.19 billion	$3.2518 billion	View	Listen
7/31/2014	Q214	$0.88	$0.95	$3.10 billion	$3.1725 billion	View	Listen
5/1/2014	Q1	$0.87	$0.85	$3.0230 billion	$3.0428 billion	View	Listen
2/11/2014	Q413	$1.91	$0.99	$2.92 billion	$3.06 billion	View	Listen
11/5/2013	Q313	$0.96	$0.98	$2.93 billion	$2.9996 billion	View	Listen
8/6/2013	Q2 2013	$1.84	$1.84	$2.88 billion	$2.8717 billion	View	Listen
5/7/2013	Q1 2013	$1.80	$1.84	$2.78 billion	$2.8296 billion	View	Listen
2/14/2013	Q4 2012	$1.60	$1.85	$2.40 billion	$2.48 billion	View	Listen
10/30/2012		$1.55	$1.56			View	N/A
8/1/2012		$1.47	$1.49			View	N/A
5/1/2012	Q1 2012	$0.73	$0.73			View	N/A
2/16/2012		$1.49	$1.58			View	N/A
11/3/2011		$1.46	$1.45			View	N/A
8/3/2011		$1.14	$1.17			View	N/A
5/2/2011		$0.95	$0.96			View	N/A
2/10/2011		$1.12	$0.70			View	N/A
11/4/2010	Q3 2010	$0.57	$0.57			View	N/A
8/2/2010	Q2 2010	$0.54	$0.53			View	N/A
4/27/2010	Q1 2010	$0.52	$0.52			View	N/A
2/10/2010	Q4 2009	$0.53	$0.53			View	N/A
11/3/2009	Q3 2009	$0.50	$0.53			View	N/A
8/4/2009	Q2 2009	$0.48	$0.51			View	N/A
4/27/2009	Q1 2009	$0.45	$0.46			View	N/A
2/10/2009	Q4 2008	$0.45	$0.47			View	N/A
11/3/2008	Q3 2008	$0.44	$0.44			View	N/A
8/4/2008	Q2 2008	$0.42	$0.45			View	N/A
4/29/2008	Q1 2008	$0.39	$0.40			View	N/A
2/13/2008	Q4 2007	$0.40	$0.40			View	N/A

(Earnings results data provided by Zacks Investment Research)

DaVita (NYSE:DVA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

DaVita (NYSE DVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 87.62%

Insider Trading History for DaVita (NYSE:DVA)

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

DaVita (NYSE DVA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/22/2018	William L Roper	Director	Sell	1,505	$68.22	$102,671.10	46,733
5/14/2018	Charles Berg	Director	Sell	338	$66.25	$22,392.50	29,776
1/16/2018	James K Hilger	Insider	Sell	3,572	$78.95	$282,009.40	33,649
12/11/2017	Charles Berg	Insider	Sell	7,048	$69.24	$488,003.52	5,359
12/8/2017	Kent J Thiry	Chairman	Sell	81,800	$68.04	$5,565,672.00
12/8/2017	Leanne M Zumwalt	VP	Sell	949	$68.19	$64,712.31	12,423
12/7/2017	James K Hilger	Insider	Sell	5,608	$69.46	$389,531.68	47,649
12/7/2017	Javier Rodriguez	CEO	Sell	22,532	$67.48	$1,520,459.36	210,317
5/15/2017	Javier Rodriguez	CEO	Sell	1,294	$66.21	$85,675.74	99,111
5/9/2017	Charles Berg	Director	Sell	8,414	$65.80	$553,641.20	34,719
5/4/2017	William L Roper	Director	Sell	12,994	$65.89	$856,174.66	45,277
8/9/2016	Michael David Staffieri	COO	Sell	20,262	$73.09	$1,480,949.58	52,279
7/11/2016	Jeanine Marie Jiganti	Insider	Sell	1,291	$78.51	$101,356.41	5,716
7/1/2016	Jeanine Marie Jiganti	Insider	Sell	4,620	$77.45	$357,819.00	7,590
5/25/2016	Pamela M Arway	Director	Sell	10,824	$77.16	$835,179.84	36,394
5/23/2016	James K Hilger	CFO	Sell	3,416	$76.79	$262,314.64	29,147
5/20/2016	Kent J Thiry	CEO	Sell	32,880	$76.99	$2,531,431.20	39,184
5/17/2016	Dennis Kogod	CEO	Sell	17,700	$77.35	$1,369,095.00	18,766
5/17/2016	Leanne M Zumwalt	VP	Sell	538	$77.08	$41,469.04	8,585
5/16/2016	James K Hilger	CFO	Sell	3,983	$75.59	$301,074.97	21,130
5/16/2016	Javier Rodriguez	CEO	Sell	36,466	$75.44	$2,750,995.04	64,264
5/16/2016	Michael David Staffieri	COO	Sell	4,934	$75.69	$373,454.46	12,279
5/12/2016	Roger Valine	Director	Sell	8,220	$76.34	$627,514.80	18,324
5/10/2016	Dennis Kogod	CEO	Sell	40,048	$76.25	$3,053,660.00	92,716
5/6/2016	John M Nehra	Director	Sell	16,314	$75.56	$1,232,685.84	36,665
4/11/2016	Javier Rodriguez	CEO	Sell	89,912	$73.51	$6,609,431.12	317,397
3/21/2016	Dennis Kogod	CEO	Sell	13,455	$72.12	$970,374.60	92,716
2/29/2016	Pamela M Arway	Director	Sell	9,026	$66.00	$595,716.00	36,070
2/23/2016	Leanne M. Zumwalt	VP	Sell	14,587	$64.25	$937,214.75
2/16/2016	Dennis Kogod	CEO	Sell	33,290	$61.99	$2,063,647.10	120,816
1/13/2016	Christopher James Schnarr	Insider	Buy	5,000	$0.68	$3,400.00
1/11/2016	Christopher James Schnarr	Insider	Buy	10,000	$0.60	$6,000.00
12/17/2015	Laura Mildenberger	insider	Sell	1,440	$68.14	$98,121.60	8,447
9/22/2015	Kim M. Rivera	insider	Sell	40,037	$75.48	$3,021,992.76	7,438
8/17/2015	Carol Anthony Davidson	Director	Sell	4,038	$79.93	$322,757.34
6/4/2015	Robert J Margolis	Chairman	Sell	31,400	$83.39	$2,618,446.00
5/28/2015	Michael David Staffieri	COO	Sell	9,050	$84.07	$760,833.50
5/19/2015	Robert J Margolis	Chairman	Sell	15,700	$83.22	$1,306,554.00
5/18/2015	James K Hilger	CFO	Sell	3,983	$82.10	$327,004.30
5/18/2015	Michael David Staffieri	COO	Sell	2,047	$82.03	$167,915.41
5/18/2015	Robert J Margolis	Chairman	Sell	15,700	$82.24	$1,291,168.00
5/11/2015	James K Hilger	CFO	Sell	8,267	$82.00	$677,894.00
5/11/2015	Jeanine Marie Jiganti	Insider	Sell	2,481	$81.95	$203,317.95
5/11/2015	John M Nehra	Director	Sell	12,278	$81.85	$1,004,954.30
4/21/2015	Robert J Margolis	Chairman	Sell	31,400	$82.40	$2,587,360.00
4/7/2015	Robert J Margolis	Chairman	Sell	15,700	$82.15	$1,289,755.00
4/6/2015	Robert J Margolis	Chairman	Sell	15,700	$81.49	$1,279,393.00
3/27/2015	Robert J Margolis	Chairman	Sell	31,400	$81.18	$2,549,052.00
3/12/2015	Robert J Margolis	Chairman	Sell	107,374	$79.24	$8,508,315.76
2/27/2015	Robert J Margolis	Chairman	Sell	21,000	$74.29	$1,560,090.00
2/19/2015	Robert J Margolis	Chairman	Sell	21,000	$73.12	$1,535,520.00
1/30/2015	Robert J Margolis	Chairman	Sell	31,400	$75.48	$2,370,072.00
1/23/2015	Michael David Staffieri	COO	Sell	21,869	$76.05	$1,663,137.45
1/16/2015	Robert J Margolis	Chairman	Sell	31,400	$74.92	$2,352,488.00
1/8/2015	Kim M Rivera	Insider	Sell	1,111	$75.10	$83,436.10
12/30/2014	Robert J Margolis	Chairman	Sell	31,400	$76.09	$2,389,226.00
12/29/2014	Robert J Margolis	Chairman	Sell	15,700	$76.09	$1,194,613.00
12/19/2014	Laura Mildenberger	Insider	Sell	1,446	$75.50	$109,173.00
12/18/2014	Robert J Margolis	Chairman	Sell	31,400	$74.67	$2,344,638.00
12/3/2014	Robert J Margolis	Chairman	Sell	31,400	$75.80	$2,380,120.00
12/1/2014	Kim M Rivera	Insider	Sell	6,503	$76.08	$494,748.24
11/21/2014	Robert J Margolis	Chairman	Sell	31,400	$75.08	$2,357,512.00
11/11/2014	Kent J Thiry	CEO	Sell	344,938	$74.52	$25,704,779.76
11/11/2014	Robert J Margolis	Chairman	Sell	250,000	$75.09	$18,772,500.00
11/10/2014	Berkshire Hathaway Inc	Major Shareholder	Buy	944,418	$74.11	$69,990,817.98
11/7/2014	R. Ted Weschler	Major Shareholder	Buy	820,018	$74.10	$60,763,333.80
11/3/2014	Roger Valine	Director	Sell	7,185	$77.85	$559,352.25
9/16/2014	John M Nehra	Director	Sell	20,000	$73.91	$1,478,200.00
9/8/2014	Kim M Rivera	Insider	Sell	1,111	$74.25	$82,491.75
8/27/2014	Leanne M Zumwalt	VP	Sell	3,214	$74.57	$239,667.98
8/11/2014	Jeanine Marie Jiganti	Insider	Sell	2,500	$72.14	$180,350.00
6/11/2014	Kim M Rivera	Insider	Sell	5,929	$71.05	$421,255.45
5/29/2014	Laura Mildenberger	Insider	Sell	5,080	$69.99	$355,549.20
5/16/2014	Dennis Kogod	COO	Sell	18,750	$67.30	$1,261,875.00	40,874
5/16/2014	Kent Thiry	CEO	Sell	17,600	$67.41	$1,186,416.00	247,950
5/15/2014	James Hilger	CAO	Sell	1,666	$67.23	$112,005.18	13,277
5/15/2014	Javier Rodriguez	CEO	Sell	7,000	$67.50	$472,500.00	64,264
5/12/2014	Dennis Kogod	COO	Sell	32,188	$68.06	$2,190,715.28	59,624
5/8/2014	Dennis Kogod	COO	Sell	32,213	$67.36	$2,169,867.68	59,624
5/7/2014	Michael David Staffieri	COO	Sell	2,633	$67.30	$177,200.90
4/2/2014	Michael David Staffieri	COO	Sell	2,867	$69.15	$198,253.05	2,633
3/20/2014	Laura Mildenberger	Insider	Sell	3,274	$70.04	$229,310.96	6,036
2/26/2014	R. Ted Weschler	major shareholder	Buy	1,159,858	$66.97	$77,675,690.26	2,191,806
2/21/2014	John Nehra	Director	Sell	40,000	$65.81	$2,632,400.00	81,766
2/18/2014	William Roper	Director	Sell	42,519	$66.37	$2,821,986.03	4,994
12/20/2013	Laura Mildenberger	Insider	Sell	10,417	$62.53	$651,375.01	6,036
12/17/2013	Allen Nissenson	Insider	Sell	2,929	$59.83	$175,242.07	2,508
12/9/2013	Berkshire Hathaway Inc	major shareholder	Buy	1,314,170	$57.84	$76,011,592.80
11/8/2013	R. Ted Weschler	major shareholder	Buy	3,700,294	$55.14	$204,034,211.16	1,095,903
7/5/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	110,309	$114.01	$12,576,329.09
7/3/2013	R. Ted Weschler	Major Shareholder	Buy	639,200	$114.78	$73,367,376.00
5/15/2013	David T Shapiro	Insider	Sell	8,779	$129.80	$1,139,514.20
5/15/2013	Dennis Kogod	COO	Sell	21,130	$129.47	$2,735,701.10
5/15/2013	James K Hilger	CFO	Sell	1,049	$130.18	$136,558.82
5/15/2013	Leanne M Zumwalt	VP	Sell	13,209	$129.59	$1,711,754.31
5/13/2013	Kent J Thiry	CEO	Sell	243,307	$129.95	$31,617,744.65
5/13/2013	Kim M Rivera	Insider	Sell	1,672	$129.70	$216,858.40
3/4/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	164,947	$119.59	$19,726,011.73
3/4/2013	Roger Valine	Director	Sell	1,390	$120.00	$166,800.00
2/27/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	211,889	$116.56	$24,697,781.84
2/22/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	224,091	$115.88	$25,967,665.08
2/19/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	323,070	$116.73	$37,711,961.10
2/5/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	32,376	$115.17	$3,728,743.92
2/4/2013	Roger Valine	Director	Sell	1,389	$116.13	$161,304.57
1/16/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	42,400	$111.33	$4,720,392.00
1/15/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	179,300	$109.67	$19,663,831.00
1/10/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	187,898	$109.54	$20,582,346.92
12/24/2012	Dennis Kogod	COO	Sell	12,736	$111.00	$1,413,696.00
12/21/2012	James K Hilger	CFO	Sell	2,073	$112.20	$232,590.60
12/6/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	635,633	$106.20	$67,504,224.60
11/29/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	679,249	$108.20	$73,494,741.80
11/26/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	412,050	$110.38	$45,482,079.00
11/16/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	132,958	$112.45	$14,951,127.10
11/12/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	548,823	$112.15	$61,550,499.45
11/7/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	139,491	$112.03	$15,627,176.73
11/2/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	254,750	$112.20	$28,582,950.00
10/26/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	257,941	$111.14	$28,667,562.74
10/17/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	63,928	$109.56	$7,003,951.68
10/12/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	217,597	$109.76	$23,883,446.72
10/9/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	67,946	$107.71	$7,318,463.66
9/28/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	282,403	$102.03	$28,813,578.09
8/8/2012	Kent J Thiry	Chairman	Sell	320,877	$96.88	$31,086,563.76
8/7/2012	William L Roper	Director	Sell	23,019	$95.95	$2,208,673.05

(Data available from 1/1/2013 forward)

DaVita (NYSE DVA) News Headlines

Source:

Date	Headline
	Insider Selling: DaVita (DVA) Director Sells 1,505 Shares of Stock www.americanbankingnews.com - May 24 at 7:50 PM
	Notable Wednesday Option Activity: DVA, GT, PXD www.nasdaq.com - May 24 at 8:15 AM
	Briefcase: DaVita doctor honored by Renal Physicians Association www.bizjournals.com - May 21 at 5:12 PM
	Form 4 DAVITA INC. For: May 15 Filed by: HEARTY JAMES O www.streetinsider.com - May 18 at 6:05 PM
	Form 4 DAVITA INC. For: May 15 Filed by: ACKERMAN JOEL www.streetinsider.com - May 18 at 6:05 PM
	Form 4 DAVITA INC. For: May 15 Filed by: DIAZ PAUL J www.streetinsider.com - May 18 at 8:29 AM
	Form 4 DAVITA INC. For: May 15 Filed by: YALE PHYLLIS R www.streetinsider.com - May 18 at 8:29 AM
	DaVita (DVA) Expected to Post Earnings of $0.98 Per Share www.americanbankingnews.com - May 17 at 7:28 PM
	Form 4 DAVITA INC. For: May 14 Filed by: BERG CHARLES www.streetinsider.com - May 17 at 8:18 AM
	DaVita (DVA) Director Sells $22,392.50 in Stock www.americanbankingnews.com - May 16 at 10:28 PM
	DaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care ... www.prnewswire.com - May 16 at 8:15 AM
	Complimentary Breakfast Technical Briefing on DaVita and Three Specialized Health Services Stocks finance.yahoo.com - May 16 at 8:15 AM
	DaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care Needs of Syrian Refugees in Jordan finance.yahoo.com - May 16 at 8:15 AM
	DaVita Sees Unusually High Options Volume (DVA) www.americanbankingnews.com - May 16 at 6:36 AM
	Critical Analysis: Catasys (CATS) vs. DaVita (DVA) www.americanbankingnews.com - May 15 at 11:16 PM
	Contrasting DaVita (DVA) and Catasys (CATS) www.americanbankingnews.com - May 15 at 3:08 AM
	Comparing Caladrius Biosciences (CLBS) & DaVita (DVA) www.americanbankingnews.com - May 13 at 11:16 PM
	DaVita (DVA) versus Caladrius Biosciences (CLBS) Financial Comparison www.americanbankingnews.com - May 12 at 1:25 PM
	BRIEF-Berkshire Hathaway Inc Reports 22.1 Percent Stake In Davita Inc As Of May 3, 2018 www.reuters.com - May 11 at 6:02 PM
	Form 4 DAVITA INC. For: May 06 Filed by: Waters Kathleen Alyce www.streetinsider.com - May 9 at 5:38 PM
	DaVita Endorses International Initiative Aimed at Helping Give Patients a Voice in Kidney Care Trials and Research finance.yahoo.com - May 8 at 8:13 AM
	RN, Case Manager, Per Diem www.bizjournals.com - May 7 at 8:16 AM
	Health Care Heroes: DaVita Celebrates its Kidney Care Nurses During National Nurses Week finance.yahoo.com - May 7 at 8:16 AM
	William Blair Brokers Raise Earnings Estimates for Davita Inc (DVA) www.americanbankingnews.com - May 7 at 2:28 AM
	Davita Inc (DVA) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - May 7 at 1:40 AM
	RN, Care Manager www.bizjournals.com - May 6 at 7:45 PM
	Davita (DVA) Issues Quarterly Earnings Results www.americanbankingnews.com - May 5 at 12:46 AM
	DaVita (DVA) Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 4 at 8:16 AM
	Edited Transcript of DVA earnings conference call or presentation 3-May-18 9:00pm GMT finance.yahoo.com - May 4 at 8:16 AM
	BRIEF-DaVita Reports Q1 Earnings Per Share $1.05 From Continuing Operations www.reuters.com - May 3 at 5:29 PM
	DaVita HealthCare Partners Inc. Q1 adjusted earnings of $1.05 per share www.nasdaq.com - May 3 at 5:29 PM
	DaVita HealthCare: 1Q Earnings Snapshot finance.yahoo.com - May 3 at 5:29 PM
	DaVita Inc. 1st Quarter 2018 Results finance.yahoo.com - May 3 at 5:29 PM
	DaVita's Sustainability Efforts Rewarded by Department of Energy finance.yahoo.com - May 2 at 5:39 PM
	Head to Head Comparison: Tivity Health (TVTY) and Davita (DVA) www.americanbankingnews.com - May 2 at 3:24 PM
	Zacks: Brokerages Anticipate Davita Inc (DVA) Will Announce Quarterly Sales of $2.96 Billion www.americanbankingnews.com - May 2 at 4:32 AM
	Davita Inc (DVA) Expected to Announce Earnings of $0.92 Per Share www.americanbankingnews.com - April 30 at 7:33 AM
	Davita (DVA) & Caladrius Biosciences (CLBS) Head to Head Survey www.americanbankingnews.com - April 29 at 9:20 AM
	Critical Analysis: Davita (DVA) vs. Tivity Health (TVTY) www.americanbankingnews.com - April 29 at 1:18 AM
	BRIEF-DaVita Says CEO Kent Thiry's Total 2017 Compensation Was $15.3 Mln www.reuters.com - April 28 at 8:24 AM
	Methodist launching data-sharing program to keep transplant candidates ready to receive finance.yahoo.com - April 27 at 5:17 PM
	Global Dialysis Market 2018 Forecast to 2022 - Key Players are Fresenius Medical Care, DaVita, Baxter and B. Braun ... www.businesswire.com - April 27 at 8:26 AM
	DaVita Continues to Improve Patient Care, Leads in Five-Star Quality Ratings finance.yahoo.com - April 27 at 8:26 AM
	Davita Target of Unusually Large Options Trading (DVA) www.americanbankingnews.com - April 26 at 7:14 AM
	Davita (DVA) Set to Announce Quarterly Earnings on Thursday www.americanbankingnews.com - April 26 at 1:40 AM
	How Highmark and a provider are working to lower the cost of dialysis care finance.yahoo.com - April 24 at 5:38 PM
	DaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve ... www.prnewswire.com - April 24 at 8:16 AM
	DaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve Transplant Readiness of Patients finance.yahoo.com - April 24 at 8:16 AM
	DaVita Recognized as a LearningElite Company by Chief Learning Officer Magazine finance.yahoo.com - April 23 at 5:16 PM
	DaVita Releases 10th Annual Community Care Report finance.yahoo.com - April 19 at 8:12 AM

DaVita (NYSE:DVA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

DaVita (NYSE:DVA) Income Statement, Balance Sheet and Cash Flow Statement

DaVita (NYSE DVA) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff